Dhan Chand: Excited to be presenting at the Global Cancer Movement conference today
Dhan Chand, Vice President of Research at Agenus, reshared a post on LinkedIn by OncoDaily, adding :
“Excited to be presenting at the Global Cancer Movement conference today.
Join me to discuss our groundbreaking work on Botensilimab in treating immunologically ‘cold’ and treatment-refractory colorectal cancers.
Let’s challenge the status quo and shape the future of cancer care.”
Quoting OncoDaily’s post:
“We’re honored to introduce Dr. Dhan Chand (USA) as a speaker at the Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer conference, taking place online from December 6-8, 2024.
Dr. Chand will present on a breakthrough in colorectal cancer treatment: Botensilimab: A Novel Multifunctional Fc-Enhanced Anti-CTLA-4 Therapy Effectively Treats Immunologically ‘Cold’ and Treatment-Refractory Colorectal Cancers.
This session will cover how this innovative therapy is offering new hope for patients with challenging and previously unresponsive colorectal cancers.
Save the date to gain insights from global leaders on the latest advancements in colorectal cancer care.”
Dhan Chand, Ph.D., is Vice President of Research at Agenus, focusing on cancer immunology, immunotherapy, and cell and molecular biology. Previously, he served as a Graduate Research Assistant and Project Co-Leader in the Department of Cell and Systems Biology at the University of Toronto.
More posts featuring Dhan Chand.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023